Vitura Health (ASX: $VIT) announcement overview

Vitura Health Limited (ASX: $VIT) has announced a significant milestone through its joint venture, Cortexa Pty. Ltd., as it becomes the first Australian company to supply Good Manufacturing Practice (GMP) Psilocybin for therapeutic use under the Therapeutic Goods Administration's (TGA) Authorised Prescriber Scheme. This marks a pioneering achievement in the Australian market, positioning Cortexa at the forefront of manufacturing and supplying GMP MDMA and Psilocybin for clinical trials and prescriptions.

Executive commentary on the milestone

Cortexa looks forward to continuing to support patients and prescribers, now and into the future.

Summary of Vitura Health's announcement

Vitura Health Limited, through its joint venture Cortexa, has achieved a significant breakthrough by supplying GMP Psilocybin for therapeutic use under the TGA's Authorised Prescriber Scheme. This accomplishment positions Cortexa as the first Australian company capable of manufacturing, supplying, and delivering both GMP MDMA and Psilocybin for clinical trials and prescriptions. The establishment of Cortexa's presence in the Australian psychedelic market, along with its national network of relationships and supply arrangements for 2024 and beyond, reflects the company's commitment to advancing therapeutic options. Vitura Health's diversified digital health business, including its subsidiaries operating in the medicinal cannabis and telehealth sectors, continues to expand its capabilities and offerings, exemplifying its adaptability and pursuit of innovative healthcare solutions.